Panel of Judges Denies MDL Status for Lipitor Lawsuits

When a pharmaceutical drug or device inflicts similar injuries on multiple people, the Judicial Panel on Multidistrict Litigation (“JPML”) may consolidate these plaintiffs into multidistrict litigation (MDL).

Recently, the JPML denied MDL status to lawsuits seeking damages related to Pfizer’s Lipitor, a drug intended to treat high cholesterol and triglycerides that has been linked to Type 2 diabetes in some women.  Many women have sued Pfizer, claiming that they developed type 2 diabetes after taking the drug.  In 2012, the Food and Drug Administration required Pfizer to add a warning label to Lipitor.  However, the warning added by Pfizer simply warns of possible increases in HbA1c and fasting serum glucose levels, and remains silent as to a diabetes connection or the importance of monitoring blood glucose levels.

Even though the federal panel ruled against the suits’ MDL status, that does not mean that injured victims are out of options.  Individual suits still continue to be filed across the country.  If you are a woman who developed type 2 diabetes after taking Lipitor, our lawyers can help you.

We are committed to seeking justice for those harmed by negligent drug manufacturers. We led the country in filing suit against Heparin, a contaminated drug connected with hundreds of deaths, and we successfully sought justice against makers of other drugs like Vioxx, Yaz, Yazmin and Ocella. Donato Borrillo, one of our class action attorneys, is also a licensed doctor with two Masters degrees. His medical knowledge and our team’s legal experience give us a strong, unique advantage when taking on pharmaceutical companies.

To schedule a free consultation, please call (888) 840-9626 toll free.

Zoll & Kranz, LLC – class action lawyers

Leave a Comment